Orbimed Advisors LLC Puma Biotechnology, Inc. Transaction History

Orbimed Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$6.5 - $10.73 $4.14 Million - $6.83 Million	-636,600 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$8.75 - $12.85 $108,071 - $158,710	12,351 Added 1.98%	636,600 $6.85 Million
Q2 2019 Aug 14, 2019	SELL	$12.3 - $35.76 $15.4 Million - $44.9 Million	-1,255,751 Reduced 66.8%	624,249 $7.93 Million
Q1 2019 May 15, 2019	SELL	$20.77 - $42.37 $14.9 Million - $30.5 Million	-718,883 Reduced 27.66%	1,880,000 $72.9 Million
Q4 2018 Feb 14, 2019	SELL	$20.07 - $46.7 $2.13 Million - $4.96 Million	-106,298 Reduced 3.93%	2,598,883 $52.9 Million
Q3 2018 Nov 14, 2018	SELL	$41.2 - $59.85 $1.14 Million - $1.66 Million	-27,700 Reduced 1.01%	2,705,181 $124 Million
Q2 2018 Aug 14, 2018	BUY	$48.3 - $68.25 $4.41 Million - $6.23 Million	91,220 Added 3.45%	2,732,881 $162 Million
Q1 2018 May 15, 2018	BUY	$59.7 - $99.25 $27.3 Million - $45.4 Million	457,126 Added 20.93%	2,641,661 $180 Million
Q4 2017 Feb 14, 2018	SELL	$93.85 - $132.45 $22.6 Million - $31.9 Million	-241,200 Reduced 9.94%	2,184,535 $216 Million
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $175 Million - $290 Million	2,425,735	2,425,735 $290 Million

101

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $127M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.